10152-79-1

Upstream product

• 1346641-14-2 C₉H₁₆O₂ 
• 10606-64-1 3-methyl-5-phenyl-tetrahydrofuran-2-one 
• 10606-65-2 Aethyl 4-chloro-2-methyl-4-phenyl-butanoat 
• 91495-76-0 1-Methyl-2-phenyl-cyclopropan-carbonsaeure-⁽¹⁾-methylester 
• 10152-83-7 (+/-)-1-methyl-2t-phenyl-cyclopropane-r-carboxylic acid amide 
• 536745-42-3 (1R,2S)-ethyl 1-methyl-2-phenylcyclopropane-1-carboxylate 
• 20780-54-5 (S)-styrene oxide 

Downstream Products

• 10606-44-7 (-)-cis-1-Methyl-2-phenylcyclopropylacetat 
• 1613473-89-4 (1R,2S)-1-methyl-2-phenylcyclopropanamine hydrochloride 
• 1613475-51-6 tert-butyl-N-[(1S,2R)-1-methyl-2-phenylcyclopropyl]-N-[2-(4-methylpiperazin-1-yl)-2-oxo-ethyl]carbamate 
• 1613474-77-3 2-[[(1R,2R)-1-methyl-2-phenyl-cyclopropyl]amino]-1-(4-methylpiperazin-1-yl)ethanone 
• 1613473-31-6 (1S,2R)-1-methyl-2-phenylcyclopropanamine 2,2,2-trifluoroacetic acid salt 
• 10606-63-0 1(R)-methyl-2(S)-phenylcyclopropanol 
• 10606-70-9 (+)-trans-1-Acetyl-1-methyl-2-phenylcyclopropan 
• 10152-83-7 (+/-)-1-methyl-2t-phenyl-cyclopropane-r-carboxylic acid amide 
• 1613475-50-5 tert-butyl-N-[(1S,2R)-1-methyl-2-phenyl-cyclopropyl]carbamate 

Relevant academic research and scientific papers

TETRAZOLE-CONTAINING 1,2-CYCLOPROPANE-CARBOXAMIDES

The present invention relates to N-(tetrazolylaryl) amide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a phar

Synthesis, biological activity and mechanistic insights of 1-substituted cyclopropylamine derivatives: A novel class of irreversible inhibitors of histone demethylase KDM1A

Histone demethylase KDM1A (also known as LSD1) has become an attractive therapeutic target for the treatment of cancer as well as other disorders such as viral infections. We report on the synthesis of compounds derived from the expansion of tranylcypromine as a chemical scaffold for the design of novel demethylase inhibitors. These compounds, which are substituted on the cyclopropyl core moiety, were evaluated for their ability to inhibit KDM1A in vitro as well as to function in cells by modulating the expression of Gfi-1b, a well recognized KDM1A target gene. The molecules were all found to covalently inhibit KDM1A and to become increasingly selective against human monoamine oxidases MAO A and MAO B through the introduction of bulkier substituents on the cyclopropylamine ring. Structural and biochemical analysis of selected trans isomers showed that the two stereoisomers are endowed with similar inhibitory activities against KDM1A, but form different covalent adducts with the FAD co-enzyme.

COMPLEMENT PATHWAY MODULATORS AND USES THEREOF

The present invention provides a compound of formula I: (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Pd(II)-catalyzed enantioselective C-H activation of cyclopropanes

Systematic ligand development has led to the identification of novel mono-N-protected amino acid ligands for Pd(II)-catalyzed enantioselective C-H activation of cyclopropanes. A diverse range of organoboron reagents can be used as coupling partners, and the reaction proceeds under mild conditions. These results provide a new retrosynthetic disconnection for the construction of enantioenriched cis-substituted cyclopropanecarboxylic acids.